Description

CJC-1295 (Mod GRF 1-29), Ipamorelin & GHRP-2 Peptide Blend

The CJC-1295 (Mod GRF 1-29), Ipamorelin, and GHRP-2 peptide blend combines three synthetic compounds frequently investigated for their potential influence on growth hormone signaling pathways. Researchers have explored these peptides individually and in combination due to their reported ability to support endogenous growth hormone release through distinct yet potentially complementary mechanisms.

CJC-1295 (Mod GRF 1-29) functions as an analog of Growth Hormone-Releasing Hormone (GHRH) and is designed to interact with GHRH receptors. Derived from the active 1-29 amino acid sequence of natural GHRH, it contains structural modifications and a Drug Affinity Complex (DAC) component that may extend its activity by promoting interaction with circulating plasma proteins.

Ipamorelin is a synthetic pentapeptide often classified as a selective growth hormone secretagogue. It is believed to activate Growth Hormone Secretagogue Receptors (GHS-R1a), commonly referred to as ghrelin receptors, potentially encouraging growth hormone release while exhibiting a high degree of receptor selectivity.

GHRP-2 (Growth Hormone Releasing Peptide-2), a synthetic hexapeptide, also targets GHS-R1a receptors. Due to its interaction with pathways associated with ghrelin signaling, researchers have investigated its potential effects on both growth hormone secretion and appetite regulation.

Chemical Profile

Molecular Formula

CJC-1295 (Mod GRF 1-29): C152H252N44O42
Ipamorelin: C38H49N9O5
GHRP-2: C45H55N9O6

Molecular Weight

CJC-1295 (Mod GRF 1-29): 3367.9 g/mol
Ipamorelin: 711.9 g/mol
GHRP-2: 817.9 g/mol

Alternative Names

Ipamorelin: Ipamorelin Acetate, IPA
GHRP-2: Pralmorelin, Growth Hormone-Releasing Peptide-2

Research and Scientific Literature

Growth Hormone Deficiency Research

Several investigations have evaluated growth hormone secretagogues in subjects experiencing growth hormone deficiencies. Research suggests that compounds such as GHRP-2, Ipamorelin, and CJC-1295 may stimulate growth hormone release through actions involving either the pituitary gland, the hypothalamus, or a combination of both pathways.

Clinical observations have indicated measurable increases in growth hormone secretion following exposure to growth hormone-stimulating peptides. In one study involving growth hormone-deficient individuals, researchers noted progressive increases in circulating growth hormone levels during treatment. The authors concluded that these compounds appeared well tolerated while demonstrating the ability to stimulate growth hormone secretion.(4)(5)

Appetite and Food Intake

GHRP-2 has been studied for its potential effects on appetite regulation. In one clinical investigation, participants receiving GHRP-2 reportedly consumed substantially more food compared with control subjects. Researchers observed simultaneous increases in growth hormone secretion, suggesting a possible connection between ghrelin receptor activation, appetite, and hormonal regulation.(6)

Ipamorelin has demonstrated similar findings in experimental models. Some studies suggest it may contribute to increased body weight and elevated food intake through interactions with pathways involved in energy balance. Researchers have also reported increases in circulating leptin levels, further supporting its possible role in appetite-related signaling.(7)

Because both Ipamorelin and GHRP-2 interact with ghrelin-associated receptors, they may exhibit complementary effects on hunger signaling when combined. CJC-1295, by contrast, has not been widely associated with appetite stimulation.

Bone Health and Bone Mineral Content

Growth hormone secretagogues have been investigated for their potential influence on bone metabolism. Among the three peptides in this blend, Ipamorelin has received notable attention in studies examining bone mineral content and density.

Experimental research involving animal models suggested that Ipamorelin may contribute to increases in bone mineral content and skeletal growth parameters. While some findings indicated enhanced bone size and cortical bone development, volumetric bone mineral density remained relatively unchanged. Researchers proposed that observed increases in bone mineral content may result from larger bone dimensions rather than changes in bone density itself.(8)

These findings have led investigators to consider whether growth hormone secretagogues may support skeletal development through mechanisms linked to endogenous growth hormone production.

Lean Mass and Nitrogen Retention

One of the most frequently studied aspects of this peptide combination is its potential influence on lean tissue development.

Research involving GHRH-deficient animal models suggested that CJC-1295 may support normal growth patterns, lean mass retention, and skeletal development. Investigators also reported increased pituitary RNA and growth hormone messenger RNA levels, which may indicate enhanced activity within somatotroph cells responsible for growth hormone production.(9)

Ipamorelin has also been evaluated for its possible effects on nitrogen metabolism. In experimental studies examining steroid-induced catabolic states, researchers observed reductions in urea nitrogen synthesis and alterations in enzymes involved in the hepatic urea cycle. These findings suggest Ipamorelin may help maintain a more favorable nitrogen balance under certain experimental conditions.(10)

Taken together, these observations have prompted ongoing investigation into the potential complementary effects of CJC-1295, Ipamorelin, and GHRP-2 on growth hormone regulation, lean tissue maintenance, and metabolic activity.

CJC-1295 (Mod GRF 1-29), Ipamorelin & GHRP-2 Peptide Blend from Medlabs Peptides is intended strictly for laboratory and research applications. Please review all applicable terms and conditions before purchasing.